C4XD NMR technology has significant potential in drug discovery and design

Conformational insights generated to feature at two conferences in September

Manchester, UK, August 28 2013 – C4X Discovery (C4XD; formerly Conformetrix), a leader in conformational drug discovery and design, is highlighting at two conferences in September the potential of its dynamic NMR technology to provide significant conformational insights. Following on from the company's recent announcement that it has solved the solution-structure of a Class B GPCR ligand in one week, the presentations will provide further insight into how the 4D structures generated by the company's MolGyrate technology can be used in drug design.

At the 17th RSC/SCI Medicinal Chemistry Symposium on September 8-11 in Cambridge, UK, the company will present a poster on 'Free Ligand Conformational Populations in Solution - A Powerful Drug Discovery Tool'. On September 25th at the Small Molecule NMR Conference in Santiago de Compostela, Spain, C4X Discovery's CSO Dr Charles Blundell will give a presentation on 'Quantification of Free Ligand Conformational Preferences by NMR and Their Relationship to the Bioactive Conformation'.

C4X Discovery has applied its technology across a wide range of ligands (small molecule drugs, peptides, macrocycles and cofactors), showing that free solution-structures can be used to accurately predict the bioactive, or 'bound', conformation when bound to their target proteins. Moreover, by measuring the behaviour of ligands in solution, C4XD can understand the dynamics of binding in a way that is unavailable from the static, single-conformation view provided by X-ray co-crystallography, providing a complementary tool for rational drug design. For targets that are not amenable to co-crystallography - which include many important GPCRs and ion channels - C4XD's technology provides a new means of driving the medicinal chemistry design cycle.

--ENDS—

For further information please contact:

C4X Discovery Ltd
Sam Williams, CEO +44 (0)7881 588947
Emma Palmer Foster, Strategic Communications Consultant +44 (0)7880 787185
communications@c4xdiscovery.com

About C4X Discovery Ltd

C4X Discovery is a Manchester-based company focused on optimising drug discovery and design. It was founded in 2008 as a spin-out from the University of Manchester. The company uses its NMR-based technology to solve the dynamic 3D structures of a broad range of biomolecules, including peptides, cofactors, oligonucleotides and carbohydrates. Since C4X Discovery's NMR technology shows what shapes active molecules prefer to adopt, it provides high-quality templates for drug discovery and design, and valuable information for drug candidate optimisation. In addition, the data is generated faster and more reliably than standard techniques such as X-ray co-crystallography or molecular modelling. C4X Discovery has solved ligand structures for large pharmaceutical companies, is developing proprietary drug programmes and has a strategic R&D collaboration with AstraZeneca signed in 2012. It has been funded since inception by life science investor Aquarius Equity Partners. www.c4xdiscovery.com.

About C4X Discovery's technology

C4X Discovery’s NMR technology determines accurate 3D structures of drug molecules in solution without the need for structural information for the target. These structures are predictive of the bioactive conformation and thereby provide researchers with valuable information on how to improve development-stage compounds. This new information should improve the efficiency and quality of the lead identification, lead optimisation and candidate selection stages of drug discovery programmes.